Combination therapy in inflammatory bowel disease patients: do we need to maximize the dose of azathioprine?
Scand J Gastroenterol
; 55(8): 920-923, 2020 Aug.
Article
em En
| MEDLINE
| ID: mdl-32689833
ABSTRACT
BACKGROUND:
The use of combination therapy of anti-TNFα and thiopurines in inflammatory bowel disease (IBD) is associated with greater efficacy and lower immunogenicity. However, the dose of thiopurine in this setting remains to be elucidated.AIM:
To compare the trough levels, anti-TNFα antibodies and the inflammatory biomarkers between three groups in combotherapy group 1 (dose of azathioprine <1 mg/kg); group 2 (dose of azathioprine ≥1 and <2 mg/kg), and group 3 (dose of azathioprine ≥2 mg/kg).METHODS:
A retrospective study was performed, selecting all patients with established diagnosis of IBD who were on combined maintenance treatment.RESULTS:
We included 99 patients, 52.5% female with median age 33 (17-61) years. Eighty patients (80.8%) were diagnosed with Crohn's disease and 19 (19.2%) with ulcerative colitis. Seventy-one (71.8%) patients were on infliximab (IFX) and 28 (28.3%) were on adalimumab (ADA). In patients treated with IFX, there were no differences in trough levels (p=.976) or formation of antibodies anti-IFX (p=.478) between groups. Moreover, there were no differences in inflammatory biomarkers CRP (p=.385) and fecal calprotectin (p=.576) among the three groups. Regarding patients treated with ADA, there were no differences in trough levels of ADA (p=.249), formation of antibodies anti-ADA (p=.706) or in inflammatory biomarkers CRP (p=.738) and fecal calprotectin (p=.269) among the three groups.CONCLUSION:
In our cohort, there were no differences between anti-TNFα trough levels, formation of anti-TNFα antibodies or inflammatory biomarkers among patients in combotherapy with azathioprine, irrespective of its dosage. In conclusion, our study suggests that maintaining therapeutic levels of anti-TNFα drugs without antibodies formation is feasible with lower doses of azathioprine, minimizing its side effects.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Azatioprina
/
Fármacos Gastrointestinais
/
Doenças Inflamatórias Intestinais
Tipo de estudo:
Observational_studies
Limite:
Adult
/
Female
/
Humans
/
Male
Idioma:
En
Revista:
Scand J Gastroenterol
Ano de publicação:
2020
Tipo de documento:
Article
País de afiliação:
Portugal